TACE Ax HCQ: Phase IB Study of Hepatic Chemoembolization Plus Axitinib and Hydrochlorquine for Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum

TACE Ax HCQ: Phase IB Study of Hepatic Chemoembolization Plus Axitinib and Hydrochlorquine for Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum
Recruiting
18 years - 99 years
All
Phase 1
10 participants needed
1 Location

Brief description of study

Liver metastases are a leading cause of death among patients with metastatic colorectal cancer. Duration of disease control is short following 2nd-line or later systemic therapy. Liver-directed therapy such as TACE has a higher response rate and improves PFS, but the benefit is still limited. Cancer cells escape ischemic cell death via autophagy and HIF activation. We hypothesize that blocking autophagy and the VEGF pathway will improve both response and PFS following TACE.

The target population are those patients with liver-only or liver-dominant metastatic colorectal cancer failing at least one line of systemic chemotherapy due to progression or toxicity.

Subjects will be recruited from the Gastrointestinal and Interventional Oncology Clinics at the University of Pennsylvania Abramson Cancer Center

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Metastatic Adenocarcinoma,colon,rectum,cancer
  • Age: 18 years - 99 years
  • Gender: All


Updated on 04 Aug 2024. Study ID: 848444

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center